High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is one of Europe's leading seed-stage investors with a total of approximately €2 billion under management across five fund generations. HTGF invests in start-ups whose business model is based on innovative, proprietary technologies. The Life Sciences sector with biotech, medtech, diagnostics, digital health, as well as start-ups in chemistry and material sciences is one of the major investment focus. Since 2005, HTGF has funded more than 760 companies across all high-tech sectors, with around a third of these in the life sciences. HTGF has overseen around 190 exits from its portfolio, including drug developers such as Cardior, Rigontec, Amal Therapeutics and MYR, life science tool providers such as Cytena, m2p-labs and SIRION Biotech and medtechs such as Synoste, Fiagon and Scopis by today. As a seed investor with the necessary appetite for risk and long-term investment horizon, HTGF typically starts with an initial investment of max. 1 million € and can reserve up to 4 million € (HTGF IV) over the company’s total life cycle. In addition to risk capital for the seed phase, the VC offers its portfolio companies access to a well-established international network of investors ranging from family offices and venture capitalists to corporates, including HTGF’s 45 fund investors from a wide range of industries. Benefit from the experience of our team and our technological and entrepreneurial expertise!